Skip to main content

Advertisement

Table 3 On-treatment virologic response for all patients (ITT population)

From: Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

n/N (%) Phase 2/3 group (N = 125) Phase 1 group (N = 16)
Week 2
  <25 IU/ml undetectable 30/125 (24.0) 1/15 (6.7)
  <25 IU/ml undetectable/detectable 99/125 (79.2) 5/15 (33.3)
Week 4
  <25 IU/ml undetectable (RVR) 90/125 (72.0) 7/15 (46.7)
  <25 IU/ml undetectable/detectable 112/125 (89.6) 15/15 (100.0)
Week 12
  <25 IU/ml undetectable (cEVR) 108/114 (94.7) 13/15 (86.7)
  <25 IU/ml undetectable/detectable 113/114 (99.1) 14/15 (93.3)
Week 24
  <25 IU/ml undetectable 102/105 (97.1) 12/13 (92.3)
  <25 IU/ml undetectable/detectable 104/105 (99.0) 13/13 (100.0)
Week 36
  <25 IU/ml undetectable 38/44 (86.4) 10/11 (90.9)
  <25 IU/ml undetectable/detectable 41/44 (93.2) 11/11 (100.0)
Week 48
  <25 IU/ml undetectable 36/39 (92.3) 9/9 (100.0)
  <25 IU/ml undetectable/detectable 37/39 (94.9) 9/9 (100.0)
EOT
  <25 IU/ml undetectable (EOTR) 105/125 (84.0) 13/15 (86.7)
  <25 IU/ml undetectable/detectable 109/125 (87.2) 14/15 (93.3)
  1. cEVR complete early virologic response, EOTR end of treatment response, ITT intent-to-treat, RVR rapid virologic response